WPD Demonstrating Highly Effective Anticancer Therapy
WPD Pharmaceuticals Announces New Publication Demonstrating Highly Effective Anticancer Therapy in Animals with Spontaneous Tumors using WPD101 Drug Candidate
Combination of IL-13RA2- and EphA2 receptor-targeted cytotoxins as highly effective anticancer therapy in dogs with spontaneous intracranial gliomas
VANCOUVER, British Columbia, Sept. 01, 2020 (GLOBE NEWSWIRE) --
WPD Pharmaceuticals Inc. (“WPD” or the “Company”) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, is excited to announce that a recently published study confirms the high therapeutic potential of IL-13RA2- and EphA2 receptor-targeted cytotoxins in the WPD101 drug candidate.
The study found the combination of these cytotoxins as a highly effective anticancer therapy in dogs with spontaneous intracranial gliomas
https://www.globenewswire.com/news-release/2020/09/01/2086830/0/en/WPD-Pharmaceuticals-Announces-New-Publication-Demonstrating-Highly-Effective-Anticancer-Therapy-in-Animals-with-Spontaneous-Tumors-using-WPD101-Drug-Candidate.html